BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, May 22, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Feb. 16, 2024

View Archived Issues
Adagio

Adagio speeds up financing rhythm with $42M SPAC deal

The slow pace of financing in med-tech appears to have stimulated cardiac arrhythmia technology developer Adagio Medical Inc. to turn to a special purpose acquisition company (SPAC) in a type of deal that has all but vanished in the last year. The company signed an agreement with Arya Sciences Acquisition Corp. IV to combine in a reverse merger deal that will result in Adagio’s listing on Nasdaq under “ADGM.” Read More
Wandercraft Atalante-X Exoskeleton

Wandercraft gets second FDA nod for self-balancing exoskeleton

Wandercraft SAS broadened its U.S. FDA clearance for the Atalante X to include rehabilitation in individuals with spinal cord injuries at levels T5 to L5. The self-balancing exoskeleton was already given the greenlight by the FDA for use in stroke rehabilitation in December 2022. “We are thrilled to have two FDA clearances, first for stroke and now spinal cord injury, in less than a year,” CEO Matthieu Masselin, told BioWorld. Read More
Shionogi Diagnostic support AI program

Shionogi, Fronteo developing AI diagnostic support models for dementia, depression

Shionogi & Co. Ltd. is partnering with Fronteo Inc. to develop artificial intelligence (AI)-based diagnostic tools to diagnose mental and neurological disorders more accurately. Read More
Philips Brightview

Philips hit with US recall for Brightview SPECT systems

The U.S. FDA reported Feb. 15 that Philips USA, a subsidiary of Amsterdam-based Royal Philips NV, recalled three models of the Brightview line of single photon emission CT (SPECT) systems due to an incident in which the system detector fell. Read More
Calculator, 100 dollar bills

Med-tech deals soar to record high in 2023, digital health still dominates

Despite a slowdown in the fourth quarter (Q4), med-tech deals concluded the year with the highest deal-value total in BioWorld MedTech’s records. In 2023, a total of $10.63 billion was raised from deals, a 33% increase over the $7.99 billion deal total in 2022. Meanwhile, annual M&A value dropped 58%, from $153.09 billion in 2022 to $64.8 billion in 2023. Read More
implantable artificial heart

Researchers develop implantable artificial heart

Researchers from the Academic Medical Center (AMC) University of Amsterdam are seeking protection for their invention of a total artificial heart which is compact, durable and mimics the natural movement of human tissue. Read More

Holiday notice

BioWorld's offices will be closed in observance of Presidents Day in the U.S. No issue will be published Monday, Feb. 19. Read More

Appointments and advancements for Feb. 16, 2024

New hires and promotions in the med-tech industry, including: Mdxhealth, Myriad Genetics. Read More

In the clinic for Feb. 16, 2024

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Lunit, Scibase. Read More

Other news to note for Feb. 16, 2024

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Angiodynamics, Autonomix, Intelligent Bio, Precisionlife, Spectrum Vascular, T2 Biosystems. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 22, 2026.
  • Acid alpha-glucosidase molecular structure isolated on black

    ‘Detargeted’ targeted gene therapy improves activity in Pompe

    BioWorld
    A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 19, 2026
  • Microscopic view of the ebola virus

    WHO declares Ebola outbreak a public health emergency of international concern

    BioWorld
    The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
  • Nxera Pharma prepares and tests new GPR17 antagonists

    BioWorld Science
    Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing